Althea makes first shipment of medicinal cannabis products to Germany

Image Credit: Althea

Australian pharmaceuticals manufacturer Althea Group Holdings Limited (ASX:AGH) announced today that it has successfully completed the first shipment of its medicinal cannabis oil products worth $1,000,000 to local partner Nimbus Health GmbH (‘Nimbus’) in Germany.

The company revealed that the initial shipment will be distributed through a large network of pharmacies, generating sales without third party wholesalers for repeat purchase orders.

Commenting on the company milestone, Althea CEO Joshua Fegan said: “Successfully shipping our first products to Germany is a huge milestone for our European expansion plans and builds on the encouraging results to date from our UK operations.”

In November 2019, Althea first signed a Memorandum of Understanding with Nimbus, a leading German pharmaceutical wholesaler specialising in the import and distribution of medicinal cannabis products.

In May 2020, Althea subsequently secured a Supply and Distribution Agreement with the Germany-based distributor.

Germany’s medicinal cannabis market is one of the largest in Europe, and it is expected to reach $12.2 billion by 2028, according to the The Germany Cannabis Report by think tank Prohibition Partners.

Anticipated growth in Germany is in part due to a favourable regulatory environment, with the country’s public and private health insurers covering the entire fee for medicinal cannabis at approval rates above 70%.

“Germany is a key market for global medicinal cannabis and is currently underserviced in terms of high-quality medicinal cannabis oil products and the education of Healthcare Professionals,” said Fegan.

“Along with exceptional patient care, these are the pillars of our business.”

Notify of
Inline Feedbacks
View all comments